Protomer is engineering next-generation protein therapeutics that can sense molecular activators in the body to automatically activate as needed. Using our proprietary protein-engineering platform, we develop therapeutic proteins that can sense molecular activators, achieve variable dosing and targeted delivery.
Protomer’s molecular engineering of protein sensors (MEPS) Platform Drug delivery at a distance
Protomer’s chemical biology-based MEPS platform enables the development of next-generation therapeutic proteins that can be controlled using molecular activators. Post-injection tuning of a therapeutic protein’s activity is a powerful approach to increase safety and efficacy. MEPS brings a truly personalized medicine approach to injectable proteins, allowing a variable dosing regimen that best fits each person’s unique physiology and response to therapy. MEPS also enables rapid turn-on, and turn-off capability for automatic activity control and targeted therapies with dual homing to reduce off-target effects.